Menu Search
Equities

Richter Gedeon Vegyeszeti Gyar Nyrt

RICHTER:BUD

Richter Gedeon Vegyeszeti Gyar Nyrt

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HUF)10,710.00
  • Today's Change-10.00 / -0.09%
  • Shares traded85.65k
  • 1 Year change+15.72%
  • Beta0.5898
Data delayed at least 15 minutes, as of Sep 18 2024 16:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform5
Hold2
Sell0
Strong Sell0

Share price forecast in HUF

The 8 analysts offering 12 month price targets for Richter Gedeon Vegyeszeti Gyar Nyrt have a median target of 12,000.00, with a high estimate of 13,124.00 and a low estimate of 9,435.00. The median estimate represents a 12.04% increase from the last price of 10,710.00.
High22.5%13,124.00
Med12.0%12,000.00
Low-11.9%9,435.00

Dividends in HUF

In 2023, Richter Gedeon Vegyeszeti Gyar Nyrt reported a dividend of 431.98 HUF, which represents a 10.39% increase over last year. The 5 analysts covering the company expect dividends of 544.88 HUF for the upcoming fiscal year, an increase of 26.13%.
Div growth (TTM)10.39%
More ▼

Earnings history & estimates in HUF

Richter Gedeon Vegyeszeti Gyar Nyrt reported annual 2023 earnings of 860.00 per share on Feb 29, 2024.
Average growth rate+16.98%
More ▼

Revenue history & estimates in HUF

Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt. had 2nd quarter 2024 revenues of 216.26bn. This was 6.12% above the prior year's 2nd quarter results.
Average growth rate+1.68%
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Rt. had revenues for the full year 2023 of 805.16bn. This was 0.30% above the prior year's results.
Average growth rate+16.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.